Bluejay Diagnostics Announces SYMON-I Study Results; IL-6 Levels Within 24 Hours of ICU Admission Predict 28-Day Mortality in Sepsis and Septic Shock Patients; Findings to Be Validated in SYMON-II Study
Portfolio Pulse from Benzinga Newsdesk
Bluejay Diagnostics announced results from the SYMON-I study, indicating that IL-6 levels within 24 hours of ICU admission can predict 28-day mortality in sepsis and septic shock patients. These findings will be validated in the upcoming SYMON-II study.
June 26, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bluejay Diagnostics' SYMON-I study results show that IL-6 levels within 24 hours of ICU admission can predict 28-day mortality in sepsis and septic shock patients. These findings will be validated in the SYMON-II study.
The positive results from the SYMON-I study could boost investor confidence in Bluejay Diagnostics' capabilities and future prospects, potentially leading to a short-term increase in stock price. The upcoming SYMON-II study for validation adds further anticipation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100